Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$29.37

-0.97 (-3.20%)

18:04
11/30/16
11/30
18:04
11/30/16
18:04

Blueprint Medicines reports 'promising' proof-of-concept data from BLU-285 trial

Blueprint Medicines announced data from its ongoing Phase 1 clinical trial evaluating BLU-285, an investigational medicine for the treatment of patients with advanced gastrointestinal stromal tumors. These data provide proof-of-concept for BLU-285, a potent, highly selective inhibitor of D842V mutant PDGFRalpha and Exon 17 mutant KIT. The data will be presented on Thursday, December 1, 2016 at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. "The clinical activity observed to date in the dose escalation portion of this Phase 1 study is promising," said Michael Heinrich, M.D., Oregon Health & Science University, an investigator for the clinical trial. "Advanced GIST is a devastating illness, marked by rapid disease progression. Seeing tumor shrinkage in 14 out of 15 PDGFRalpha-driven GIST patients at this point in the study is notable. I am also excited to see tumor shrinkage in four out of the six KIT-driven GIST patients treated at the higher dose levels, indicating the potential for increased clinical activity as we continue to dose-escalate. Given these encouraging early data for this investigational medicine, I believe BLU-285 could be transformative for patients with advanced GIST." BLU-285 is currently being evaluated in the dose escalation stage of a Phase 1 clinical trial in patients with unresectable PDGFRalpha-driven GIST and patients with treatment-resistant KIT-driven GIST. As of the data cutoff date of November 1, 2016, 36 patients had been treated in the dose escalation portion of the Phase 1 clinical trial at seven dose levels, including 18 patients with PDGFRalpha-driven GIST and 18 patients with KIT-driven GIST. The median age was 61, and the median number of prior tyrosine-kinase inhibitor regimens was 3.5. As of the data cutoff date of November 1, 2016, BLU-285 was observed to be well-tolerated at all doses. The majority of adverse events (AEs) reported by investigators were Grade 1 or 2. Across all grades, AEs reported by investigators most commonly included nausea, vomiting, peripheral edema, fatigue and constipation. Investigators reported treatment-related Grade 3 AEs in three patients: nausea and vomiting; anemia and intratumoral hemorrhage; and hypophosphatemia. No dose-limiting toxicities or drug-related Grade 4 or 5 AEs were reported, and no patients discontinued BLU-285 due to treatment-related adverse events. A maximum tolerated dose has not been reached, and enrollment in the dose escalation portion of the Phase 1 clinical trial is ongoing. Based on the favorable safety profile and encouraging clinical activity observed to date in the Phase 1 clinical trial for BLU-285 for the treatment of advanced GIST, Blueprint Medicines will continue to enroll patients in the dose escalation portion of this clinical trial until a MTD or a lower recommended dose for further clinical evaluation has been established. Enrollment in the expansion cohorts for this Phase 1 clinical trial is expected to begin in the first half of 2017. Blueprint Medicines plans to enroll approximately 35 patients with advanced GIST in the expansion cohorts. We also plan to accelerate our evaluation of expanded development options for BLU-285 in GIST, including opportunities to move to earlier lines of therapy and possible combinations.

  • 01

    Dec

  • 03

    Dec

  • 05

    Dec

BPMC Blueprint Medicines
$29.37

-0.97 (-3.20%)

05/27/16
RAJA
05/27/16
INITIATION
Target $23
RAJA
Outperform
Blueprint Medicines initiated with an Outperform at Raymond James
Raymond James analyst Chris Raymond initiated Blueprint Medicines with an Outperform rating and $23 price target. The analyst thinks Blueprint's unique kinase inhibitor discovery platform is well-positioned to generate novel compounds for years to come. Coupling this with a clinical stage pipeline that remains wholly-owned, key proof-of-concept data for two products,BLU-285 and BLU-554, in three different indications by year end 2015, and a valuation offering favorable risk/reward.
08/05/16
ADAM
08/05/16
INITIATION
Target $26
ADAM
Buy
Blueprint Medicines initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Blueprint Medicines with a Buy and $26 price target.
11/11/16
ADAM
11/11/16
NO CHANGE
Target $35
ADAM
Buy
Blueprint Medicines price target raised to $35 from $26 at Canaccord
Canaccord analyst Arlinda Lee raised her target on Blueprint Medicines to $35 from $26 following company updates on its pipeline of novel, rationally designed, target kinase inhibitors. The analyst increased her probability of success for the company's three programs to 25% from 20% and maintained her Buy rating on Blueprint Medicines shares.
11/29/16
WEDB
11/29/16
NO CHANGE
WEDB
Blueprint Medicines data 'highly encouraging,' says Wedbush
Wedbush analyst David Nierengarten says that Phase I data on Blueprint's BLU-554 for advanced HCC was "highly encouraging." The analyst says that the drug performed well compared with approved HCC therapies. Specifically, he believes that the 10% overall response rate and the fact that four out of ten patients showed radiographic tumor reductions are "promising" signs. The analyst reiterates a $41 price target and an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

FEYE

FireEye

11:45
06/27/17
06/27
11:45
06/27/17
11:45
Options
FireEye call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

11:45
06/27/17
06/27
11:45
06/27/17
11:45
General news
Treasury's $40 B 4-week bill sale was poorly subscribed »

Treasury's $40 B…

BT

BT Group

$18.68

0.06 (0.32%)

11:42
06/27/17
06/27
11:42
06/27/17
11:42
Upgrade
BT Group rating change  »

BT Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
06/27/17
06/27
11:35
06/27/17
11:35
General news
Treasury Option Action: a round of call buying in the belly »

Treasury Option Action: a…

OSUR

OraSure

$15.72

0.17 (1.09%)

11:31
06/27/17
06/27
11:31
06/27/17
11:31
Recommendations
OraSure analyst commentary  »

OraSure price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

XLF

Financial Select Sector

$24.19

0.17 (0.71%)

11:30
06/27/17
06/27
11:30
06/27/17
11:30
Options
SPDR Financial calls outpace puts nearly 25:1 »

SPDR Financial calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KITE

Kite Pharma

$100.43

-0.23 (-0.23%)

11:25
06/27/17
06/27
11:25
06/27/17
11:25
Options
Kite Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

ANY

Sphere 3D

$0.20

0.0275 (16.08%)

11:25
06/27/17
06/27
11:25
06/27/17
11:25
Conference/Events
Sphere 3D to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MRK

Merck

$66.14

0.215 (0.33%)

11:20
06/27/17
06/27
11:20
06/27/17
11:20
Periodicals
Merck confirms computer network 'compromised' by global hack »

Merck stated in a series…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

11:20
06/27/17
06/27
11:20
06/27/17
11:20
General news
Fed's Harker still backs another rate hike this year »

Fed's Harker still…

BLK

BlackRock

$425.20

0.51 (0.12%)

11:17
06/27/17
06/27
11:17
06/27/17
11:17
Hot Stocks
BlackRock to acquire Cachematrix »

BlackRock has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
06/27/17
06/27
11:17
06/27/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
06/27/17
06/27
11:16
06/27/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/27/17
06/27
11:15
06/27/17
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

PSX

Phillips 66

$80.96

0.72 (0.90%)

, CVX

Chevron

$104.76

0.62 (0.60%)

11:11
06/27/17
06/27
11:11
06/27/17
11:11
Hot Stocks
Chevron Phillips Chemical names Mark Lashier CEO »

Chevron Phillips Chemical…

PSX

Phillips 66

$80.96

0.72 (0.90%)

CVX

Chevron

$104.76

0.62 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

11:10
06/27/17
06/27
11:10
06/27/17
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

ALDR

Alder Biopharmaceuticals

$18.70

-1 (-5.08%)

11:03
06/27/17
06/27
11:03
06/27/17
11:03
Recommendations
Alder Biopharmaceuticals analyst commentary  »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

AA

Alcoa

$32.33

1.15 (3.69%)

11:00
06/27/17
06/27
11:00
06/27/17
11:00
Options
Alcoa attracts call buying »

Alcoa attracts call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
06/27/17
06/27
11:00
06/27/17
11:00
General news
FX Action: USD-CAD »

FX Action: USD-CAD fell…

11:00
06/27/17
06/27
11:00
06/27/17
11:00
General news
Breaking General news story  »

Philadelphia Federal…

HCC

Warrior Met Coal

$15.88

-0.31 (-1.91%)

10:58
06/27/17
06/27
10:58
06/27/17
10:58
Downgrade
Warrior Met Coal rating change  »

Follow-up: Warrior Met…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BV

Bazaarvoice

$4.80

-0.1 (-2.04%)

10:56
06/27/17
06/27
10:56
06/27/17
10:56
Conference/Events
Bazaarvoice management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

CBI

CB&I

$16.50

2.1 (14.58%)

, TOSBF

Toshiba, also use TOSYY

$2.69

0.03 (1.13%)

10:55
06/27/17
06/27
10:55
06/27/17
10:55
Periodicals
Court rules for Chicago Bridge in Westinghouse case, Reuters says »

The Delaware Supreme…

CBI

CB&I

$16.50

2.1 (14.58%)

TOSBF

Toshiba, also use TOSYY

$2.69

0.03 (1.13%)

TOSYY

Toshiba, also use TOSBF

$15.91

-0.065 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
06/27/17
06/27
10:55
06/27/17
10:55
Conference/Events
Federal Reserve Bank of Philadelphia President speaks on economic outlook »

Philadelphia Federal…

LTRX

Lantronix

$2.37

-0.08 (-3.27%)

10:54
06/27/17
06/27
10:54
06/27/17
10:54
Conference/Events
Lantronix management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.